July 27, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Acquisition of Laos Anticancer Drug Company Sailin biopharma.
The acquisition is to strengthen BIOSspring's technological advantages and manufacturing capacity in the field of anticancer drugs. SAILIN's product line is mainly focused on the field of oral targeted therapy.
The acquisition is expected to be completed before the end of this year. After the acquisition and integration, BioSpring will not continue to operate the SAILIN brand, but will adopt a single product system.
Through this acquisition, BioSpring has obtained mature formulation processes and manufacturing capacity for at least 12 anticancer drugs.And the necessary development and manufacturing conditions for the continuous development of new products in the field of anticancer drugs.
Samuel, founder and CEO of BioSpring, said: "This acquisition helps us accelerate our planned product pipeline: Targeted Therapy, Antiviral Medications, Consumer Brand..” “We hope that by this time next year, all three product lines will form a certain competitive group.”
About BioSpring
Founded in 2022 at the Vientiane Saiseta Comprehensive Development Zone in Laos, BioSpring is the country's fastest growing generic drug manufacturing company and the country's first pharmaceutical company targeting the international market, serving Asia, Africa, Europe and Latin America Americas and many other countries and regions.
Visit:www.biospring.ltd to know more information.
About Sailin Biopharma
Sailin biopharmaceutical (Laos) co., LTD., and the construction in 2019, is currently the largest and the most technologically advanced Laos anticancer and antiviral drugs production enterprise joint pharmaceutical group co., LTD., a subsidiary of the country's fastest growing large pharmaceutical companies.
Sailin pharmaceutical is a pharmaceutical enterprise management practices, in vientiane Rosetta park covers an area of 60 mu, raw material production and preparation production is equal to one, the company has more than 152 employees.
Visit: www.sailin-bio.com/en/ to know more information.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.
Source: BioSpring Group.LTD
View source version on EINPresswire.com: https://www.einpresswire.com/article/583208309/lao-pharmaceutical-company-biospring-announces-acquisition-agreement-with-cancer-drug-company-sailin-biopharma
October,24,2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") that it has reached preliminary cooperation intentions with clients at the "Medlab Asia & Asia Health 2022" event in Bangkok. At the event site, BioSpring's business team communicated and communicated with customers from Nepal, Bhutan, and Timor-Leste, and the two parties reached preliminary intentions on business cooperation and product registration submissions. The client…
August 18, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Phase 1 of the manufacturing unit was constructed and delivered. This time, the delivery of the manufacturing unit constructed according to the ICH1-GMP2 standard is the first step for BioSpring to serve global users. With the strong support and joint efforts of the Vientiane government of Laos and the Saysettha Comprehensive Development Zone,…
BioSpring is the first third-party formula manufacturing pharmaceutical company in Laos to expand the global market Long-term development goals include serving Southeast Asia, South Asia, Arabia, Eastern Europe, Central Asia, West Asia, Africa, Latin America and other markets Planned product lines include epidemiological drugs, oncology drugs, rare disease drugs, and long-term care and companion animal drugs June 14, 2022, Vientiane, Laos–BioSpring…
